文献速递炎症性肠病

维得利珠单抗治疗炎症性肠病的长期安全性

Long-term safety of vedolizumab for inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-09-02

GEMINI长期安全性研究为3期开放标签研究,纳入894例溃疡性结肠炎和1349例克罗恩病患者,每4周静脉给予维得利珠单抗300 mg。中位累积暴露42.4个月(UC)和31.5个月(CD),不良事件发生率93%(UC)和96%(CD),未发现新的安全性信号,支持长期使用。

要点

  • 维得利珠单抗长期安全性良好,未出现意外或新的安全性问题。
  • 不良事件发生率UC 93%、CD 96%,严重不良事件UC 31%、CD 41%。
  • 400治疗周时临床缓解率UC 33%、CD 28%。

核心结论

  • 维得利珠单抗的安全性特征保持良好,未出现意外或新的安全性问题。
  • 这些结果进一步确立了维得利珠单抗的安全性,并支持其长期使用。

研究设计与样本

  • 3期开放标签GEMINI长期安全性(LTS)研究,于2009年5月启动。
  • 纳入来自既往四项临床试验的UC或CD患者以及未接受过维得利珠单抗的患者。
  • 共纳入UC患者894例、CD患者1349例,每4周静脉给予维得利珠单抗300 mg。
  • 中位累积暴露时间UC为42.4个月(范围0.03-112.2),CD为31.5个月(范围0.03-100.3)。
  • 疗效和患者报告结局为探索性终点。

主要发现

  • 8年间,不良事件发生率UC为93%、CD为96%,最常见为UC(36%)和CD(35%)疾病加重。
  • 严重不良事件发生率UC为31%、CD为41%。
  • 因不良事件停用维得利珠单抗者UC为15%、CD为17%。
  • 感染、恶性肿瘤、输注相关反应或肝脏事件未见新趋势,未出现进行性多灶性白质脑病病例。
  • 共10例死亡(UC 4例、CD 6例),其中2例被当地研究者认为与药物相关(西尼罗病毒感染相关脑炎和肝细胞癌)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vedolizumab, a gut-selective α4 β7 integrin antibody, is approved for moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). AIM: To report the final results from the vedolizumab GEMINI long-term safety (LTS) study. METHODS: The phase 3, open-label GEMINI LTS study (initiated May 2009) enrolled patients with UC or CD from four prior clinical trials and vedolizumab-naïve patients. Vedolizumab LTS was evaluated; efficacy and patient-reported outcomes were exploratory endpoints. RESULTS: Enrolled patients (UC, n = 894; CD, n = 1349) received vedolizumab 300 mg IV every 4 weeks; median cumulative exposure was 42.4 months (range: 0.03-112.2) for UC and 31.5 months (range: 0.03-100.3) for CD. Over 8 years, adverse events (AEs) occurred in 93% (UC) and 96% (CD) of patients, with UC (36%) and CD (35%) exacerbations most frequent. Serious AEs were reported for 31% (UC) and 41% (CD) of patients. Vedolizumab discontinuation due to AEs occurred in 15% (UC) and 17% (CD) of patients. There were no new trends for infections, malignancies, infusion-related reactions, or hepatic events, and no cases of progressive multifocal leukoencephalopathy. Of the ten deaths (UC, n = 4; CD, n = 6), two were considered drug-related by local investigators (West Nile virus infection-related encephalitis and hepatocellular carcinoma). Continuous vedolizumab maintained clinical response long-term, with 33% (UC) and 28% (CD) of patients in clinical remission at 400 treatment weeks. CONCLUSIONS: The safety profile of vedolizumab remains favourable with no unexpected or new safety concerns. These results further establish the safety of vedolizumab and support its long-term use (NCT00790933/EudraCT 2008-002784-14).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Loftus EV, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 32876349. doi:10.1111/apt.16060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。